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ABSTRACT: Ovarian cancer represents the seventh most commonly diagnosed cancer 
worldwide. Currently, platinum-based chemotherapy resistance and multiple severe side 
effects represent a major hurdle for ovarian cancer patients who relapse. Therefore, there is a 
need to enlarge the chemical space of medicinal chemistry, and in this regard, the 
incorporation of silicon in a drug scaffold offers great potential. Herein, we report on the 
development of a withaferin A-silyl ether library, 30 analogues are reported for the first time. 
Cytotoxicity assays on human epithelial ovarian carcinoma cisplatin-sensitive and -resistant 
cell lines identified several analogues displaying nanomolar-potency, higher than the lead 
compound and reference drug. This cytotoxic potency is also coupled with a good selectivity 
index on a non-tumoral cell line. Cell cycle analysis of two potent analogues revealed cell 
death by apoptosis without indication of a cell cycle arrest in G0/G1 phase. The structure-
activity relationship (SAR) and in silico ADME studies demonstrated that the incorporation 
of silicon and a carbonyl group at C-4 in the WA-framework enhances potency, selectivity 
and drug-likeness. These findings reveal analogues 22, 23 and 25 as potential candidates for 
clinical translation in patients with relapsed ovarian cancer.  
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INTRODUCTION 
Ovarian cancer (OC) represents the seventh most commonly diagnosed cancer worldwide.
1
 
Current treatment entails cytoreductive surgery followed by platinum- or taxane-based 
chemotherapy.
2
 Initially, OC responds positively in 70 to 80% of the cases. However, nearly 
70% of patients suffer a relapse within 6 months of the last chemotherapeutic cycle, which is 
attributed to patients eventually developing resistance to carboplatin and paclitaxel adjuvant 
chemotherapy.
3
 Therefore, chemotherapy resistance, whether primary (i.e., intrinsic) or 
secondary (i.e., acquired), represents a major hurdle in OC treatment.
4
 Additionally, 
platinum-based chemotherapy is associated with multiple severe side effects (e.g. nausea, 
myelosuppression, neurotoxicity, nephrotoxicity, hepatotoxicity and ototoxicity).
5
 Thus, there 
is an urgent need for new second-line therapies to improve the prognosis of patients with 
relapsed OC. As an alternative treatment strategy to reduce the side effects and resistance 
caused by cis-platinum-based chemotherapy a number of combinations with other 
compounds have been explored. In this sense, Natural Products (NPs) are ideal candidates for 
OC chemoprevention or adjuvants of conventional chemotherapy. Recently, Pistollato and 
co-workers
6 
have reviewed NPs targeting OC, describing the molecular mechanisms 
underlying their effects. These NPs, which include curcumin, epigallocatechin 3-gallate, 
resveratrol, sulforaphane and Withaferin A, are characterized by long-term safety and 
negligible and/or inexistent side effects, and have been proposed as possible adjuvants to 
traditional chemotherapy.
 
 
Withaferin A (WA), a natural steroidal lactone, is a promising drug candidate multi-
targeting various cancer hallmarks.
7
 WA down-regulates the Notch, Akt and bcl-2 pathways 
and causes growth inhibition and apoptosis induction in ovarian carcinoma cell lines, CaOV3 
and SKOV3.
8
 Studies conducted on various epithelial cancer cell lines (cisplatin-sensitive 
A2780, cisplatin-resistant variant A2780/CP70, and p53 mutant CaOV3) revealed a 
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synergetic effect of WA in combination with doxorubicin
 9
 and cisplatin
10
 on cell death 
through the generation of ROS-mediated autophagy, leading to DNA damage and induction 
of apoptosis. The authors suggested this synergetic therapy could minimize/eliminate the side 
effects and induction of drug resistance associated with high drug doses. In addition, WA in 
combination with liposomal preparation of doxorubicin targets aldehyde dehydrogenase I 
positive cancer stem cells in OC.
11 
Moreover, WA alone and in combination with cisplatin 
targets putative cancer stem cells,
12, 13
 suggesting that this may present more efficacious 
therapy for OC. Despite the recognized potential of WA as an antitumor agent, its application 
in clinical oncology is non-existent. 
Furthermore, the medicinal applications of organosilicon molecules are particularly 
interesting because differences in their chemical properties can contribute to enhancing 
potency and improving pharmacological attributes.
14
 These differences offer the potential for 
unique and/or specific interactions between an organosilicon molecule and a biological 
macromolecule. In fact, there are many examples demonstrating that the incorporation of silyl 
groups provides a general strategy to increase size and lipophilicity for drug design. Although 
there are no marketed drugs containing silicon, some silicon compounds have entered human 
clinical trials.
15 
Though still a growing area, the incorporation of silicon in drug scaffolds 
may well offer great potential for enlarging the chemical space of medicinal chemistry. 
Moreover, computational methods have become a promising tool for identifying active lead 
compounds and are being used with the pipeline of drug discovery in most pharmaceutical 
companies.
16
 Thus, theoretical prediction of pharmacokinetic properties i.e. ADMET 
(absorption, distribution, metabolism, excretion, and toxicity) play a key role in drug 
discovery, since an unfavorable ADMET has been identified as the major cause of failure of 
candidate molecules in drug development.
17
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Previously, we have reported that incorporation of silyl ether substituents in the WA-
framework enhance its cytotoxic effect on HeLa (carcinoma of the cervix), A-549 (lung 
carcinoma), and MCF-7 (breast adenocarcinoma) human cancer cell lines, whereas a ketone 
group at C-4 increases selectivity.
18,19 
Moreover, the induction of apoptosis by 27-O-(tert-
butyldimethylsilyl)-4-dehydroxy-4-oxo-withaferin A without necrosis under extreme 
experimental conditions has drawn our attention to these organosilicon analogues.
18 
Therefore, encouraged by the previous work on WA targets ovarian cancer cells, and the 
expectation of bio-organosilicon in drug design, efforts to enlarge the chemical space of WA 
to improve its clinical potential as anticancer agent are continuing. The current study reports 
the design, synthesis and evaluation of a WA-silyl ether library with enhanced ovarian cancer 
cell cytotoxicity compared to the lead compound and reference drug. Furthermore, two 
analogues were investigated for their ability to induce apoptosis, confirming previous studies 
on this type of scaffold.
19 
In addition, extensive structure−activity relationship (SAR) and in 
silico ADME studies were employed to understand the pharmacokinetic properties of this 
series of WA-analogues. 
 
RESULTS AND DISCUSSION 
1. Chemistry. When silicon is incorporated into an organic compound, the chemical and 
physical differences contributed by the silyl group can provide compounds with unique 
properties that are relevant for medicinal chemistry.
14  
Withaferin A is a C28 ergosterane-type steroid with a δ-lactone ring between C-22 and C-
26 in the side chain. To refine structural features and enhance the anticancer profile of WA, a 
suitable starting material from Withania aristata,
18
 a library of WA-silyl ether analogues (2-
22 and 24-34) were designed and synthesized (Schemes 1-4 and detailed in the Supporting 
Information S32-S46).  
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The synthesis of this WA-library was carried out using silyl chloride with different 
electronic and steric properties, such as hydrophobicity, size and aromaticity. The first step in 
this task was to investigate the modification of the hydroxyl groups at C-4 and C-27 by 
converting them into silyl ethers. Thus, 27-silyl ether (2-10) and 4,27-disilyl ether (11-16) 
analogues were synthesized following the strategy outlined in Scheme 1.  
Scheme 1. Synthesis of Withaferin A-silyl Ether Analogues 2-16
a
 
a
Reagents and conditions: (i) R1R2R3SiCl, DMAP, CH2Cl2, rt. 
It is worth noting that treatment of WA (1) with DMIPSiCl afforded, in addition to the 
expected silyl ethers 18 and 19, analogues 17 and 20, which were formed by selective 
silylation of the secondary alcohol at C-4 and Michael addition of imidazole to the enone 
system in the WA-framework, respectively (Scheme 2).  
Scheme 2. Synthesis of Withaferin A-silyl Ether Analogues 17-20
a 
 
 
a
Reagents and conditions: DMIPSiCl, imidazole, DMAP, CH2Cl2, rt. 
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Previously reported structure-activity relationship (SAR) studies on withanolides,
16 
indicated that compounds bearing a ketone at C-4 have a selective pharmacological profile.
 
Encouraged by these results, the synthesis of analogue 23 was carried out following the 
strategy outlined in Scheme 3. Firstly, selective protection of the primary alcohol in WA (1) 
with TBDMSiCl yielded the corresponding silyl ether derivative 21, whose oxidation by 
treatment with Collins reagent afforded the ketone analogue 22. Further cleavage of the 
protecting group in 22 with carboxylic acid resin led to the 4-dehydro-WA analogue 23.  
Scheme 3. Synthesis of Withaferin A-analogues 21-23
a 
a
Reagents and conditions: (i) TBDMSiCl, imidazol, DMAP, CH2Cl2, r.t.; (ii) CrO3, py, 
CH2Cl2, rt, 15 min; (iii) Dowex (50WX8-200), acetone, rt, 24 h. 
 
Derivatives 24-34 bearing both a 4-ketone and a 27-silyl ether group were prepared from 
compound 23 by silylation at C-27 with different silyl chloride reagents as shown in Scheme 
4 (Supporting Information, S41-S46).  
Scheme 4. Synthesis of 4-Oxo-withaferin A-silyl Ether Analogues 24-34
a 
 
a 
Reagents and conditions: (i) R1R2R3SiCl, imidazol, DMAP, CH2Cl2, rt. 
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Among the former synthetic analogues, 30 out of 33 are reported for the first time. The 
structures of the new compounds were elucidated by HRMS and NMR analysis (Supporting 
information, S2-S31), whereas those of the previous reported analogues, compounds 21-23 
were elucidated by comparison of their spectral data with those reported in the literature.
18
 
 
2. Biological Evaluation.  
Antiproliferative activity. The in vitro antiproliferative activity of lead compound 1 and 
derivative 23 (4-oxo-WA), and their silyl-analogues 2-22 and 24-34, respectively, were 
evaluated on two human epithelial ovarian tumor cell lines, cisplatin-sensitive (A2780) and 
cisplatin-resistant (A2780/CP70) cells, and on the non-carcinoma cell line ARPE-19 (human 
retinal pigment epithelial), the latter used to test for selectivity. 
Cytotoxic evaluation (Table 1, and Supporting Information, S47) against the cisplatin-
sensitive cell line revealed that the cytotoxicity of 11 analogues (compounds 3-5, 7-9, 13, 15, 
20, 22, and 23) was higher than the widely known anticancer WA (1, IC50 32.7 nM) and the 
reference drug (carboplatin, IC50 2.6 µM), exhibiting IC50 values ranging from 7.3 to 32 nM. 
Moreover, it is noteworthy that silyl ether analogues bearing a dimethyloctyl (7 and 13, IC50 
10 and 1.5 nM, respectively) or a dimethylphenyl (15, IC50 2.9 nM) moiety as well as 
oxidation at C-4 (23, IC50 7.3 nM) are favorable trends for optimal cytotoxicity against 
A2780 cells, improving activity by 3.2- to 21.8-fold compared to lead compound 1. 
Curiously, potency of the imidazole derivative 20 (IC50 20 nM) was slightly higher than the 
lead compound 1, which is opposite to previously reported SAR of withanolides in which the 
enone system is essential for the anticancer activity.
20
 On the other hand, functional group 
interconversion of alcohols in WA by a trihexylsilyl (analogues 6 and 29) or a tripropylsilyl 
(derivative 12) moiety was particularly detrimental furnishing completely inactive analogues. 
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Drug resistance is a major obstacle for first line chemotherapy in ovarian cancer treatment.
4
 
Taking into consideration the promising results obtained for WA-silyl-analogues assayed on 
A2780 cisplatin-sensitive cell line, this series of compounds was tested for efficacy on a 
human ovarian carcinoma cisplatin-resistant (A2780/CP70) cell line. The results (Table 1) 
indicated that 15 analogues showed from similar (7-10, 14, 15, 18, 27 and 30) to slightly 
improved (5, 13, 17, 20, 25 and 26) profile than the lead compound, WA (IC50 32 nM). 
Moreover, potencies of target compounds 2, 3 and 23 on A2780/CP70 cells, exhibiting IC50 
values ranging from 1 to 12.8 nM, were significantly improved from 2- to 30-fold compared 
to compound 1. Regarding analogues with a drastic loss of activity, again analogues 6 and 29 
and the disilyl ether derivatives 12 and 16 were from 794- to 364-fold less active than WA.  
After confirming that some of the newly-synthesized analogues showed potent activity 
against both human epithelial ovarian tumor cell lines, cytotoxicity against a non-carcinoma 
cell line (ARPE19, human retinal pigment epithelial cells) was evaluated for all derivatives to 
test for selectivity (Table 1). We assume that a selectivity index (SI) value higher than two 
indicates a good selectivity for inducing cytotoxicity in tumor cell lines as compared to those 
in non-cancerous cells, according to Suffness.
21
 Among the evaluated compounds, 25 of them 
showed selectivity to a some extent (SI > 2) in the non-carcinoma (ARPE19) cell line with 
respect to the A2780 cell line. Selectivity was observed for the most potent analogues, 7, 8, 
13, 15, 20, 22 and 23 (SI ranging from 2.6 to 212.0), but also for those compounds equipotent 
to WA, analogues 18, 25, and 34 (SI 191.2, 53.5 and 58.6, respectively). Similarly, SI was 
higher than two for 21 analogues regarding the A2780/CP70 cell line. The most active 
analogues on this cell line, compounds 2, 3, 17, 20, 23, 25 and 26, showed SI values from 2.3 
to 93.5. In addition, analogues 10, 18 and 30 with a similar profile to WA were not cytotoxic 
on the non-carcinoma cell line (SI 79.1, 185.7 and 62.9, respectively).  
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Table 1. Cytotoxic Activity (IC50, nM)
a
 of WA-analogues
b
 on Human Ovarian 
Carcinoma Cell Lines,
c
 and on a non-Carcinoma Cancer Cells (ARPE19). 
compd 
 
A2780  A2780/CP70  ARPE19  
SI
d
  
A2780 
 
SI
d 
A2780/CP70 
1    32.7 ± 0.2   32.0 ± 2.0   37.0 ± 14.0  1.1  1.2 
2    > 100   12.8 ± 2.0   30.0 ± 10.0  -  2.3 
3    32.0 ± 2.0   3.6 ± 1.4   30.0 ± 0.6  0.9  8.3 
4    30.0 ± 2.0   62.0 ± 20.0   62.0 ± 30.0  2.1  1.0 
5    27.0 ± 4.0   22.0 ± 0.3   260.0 ± 210.0  9.6  11.8 
7    10.0 ± 0.7   33.0 ± 10.0   32.0 ± 5.0  3.2  1.0 
8    27.0 ± 10.0    31.0 ± 2.0   86.0 ± 16.0  3.2  2.8 
9    22.0 ± 5.0   28.3 ± 0.3   70.0 ± 10.0  3.2  2.5 
10    46.0 ± 9   29.0 ± 6.0   2295.0 ± 25.0  49.9  79.1 
13    1.5 ± 0.5   24.9 ± 10.0   318.0 ± 61.0  212.0  12.8 
14    33.0 ± 0.5   27.5 ± 5.0   92.0 ± 30.0  2. 8  3.4 
15    2.9 ± 1.0   29 ± 0.005   309.0 ± 40.0  106.6  10.7 
17    34.0 ± 1.0   23.0 ± 9.0   310.0 ± 200.0  9.1  13.5 
18    34.0 ± 0.6   35.0 ± 0.4   6500.0 ± 150.0  191.2  185.7 
20    20.0 ± 7.0   19.0 ± 10.0   52.0 ± 10.0  2.6  2.7 
21   47.5 ± 19.0   > 100   12.4 ± 1.0  0.3  0.1 
22   17.0 ± 10.0   > 100   1660.0 ± 90.0  97.7  11.3 
23    7.3 ± 6.0   < 1   32.0 ± 2.0  4.3  >32.0 
24   41.0 ± 5.0   68.8 ± 8.0   820.0 ± 300.0  20.0  11.9 
25    35.0 ± 10.0    20.0 ± 0.2   1870.0 ± 70.0  53.5  93.5 
26    69.0 ± 20.0   21.0 ± 6.0   1740.0 ± 340.0  25.2  82.9 
27    35.0 ± 6.0  35.0 ± 1.0   37.5 ± 4.0  1.1  1.1 
28    53.0 ± 40.0   > 100  617.0 ± 500.0  11.6  - 
30    43.0 ± 0.2   34.0 ± 0.2   2140.0 ± 100.0  49.8  62.9 
33    59.0 ± 10.0   > 100  2305.0 ± 270.0  39.1  - 
34    35.0 ± 10.0   > 100   2050.0 ± 350.0  58.6  - 
 
a 
IC50 values (nM) of WA-silyl analogues were determined as described in the Biological 
Studies section. Carboplatin was used as a reference drug (IC50 2.6, 44.9 and 4.6 µM on 
A2780, A2780/CP70 and ARPE19 cell lines, respectively). Results are expressed as the mean 
± standard deviation of three independent experiments performed in duplicate. 
b
 WA-
analogues exhibiting IC50 values ≤ 100 nM. 
c 
Human ovarian carcinoma cisplatin-sensible 
(A2780) and cisplatin-resistant (A2780/CP70) cell lines 
d 
SI, Selectivity Index.  
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The overall results of the biological assays identified analogues 13, 15, 22 and 23 on the 
cisplatin-sensitive cell line, and even more noteworthy, analogues 3, 17, 23, 25 and 26 on the 
cisplatin-resistant cell line as having significantly improved activity profiles compared to lead 
compound 1. These profiles were coupled with remarkable selectivity on the non-tumoral cell 
line and, therefore, are suitable for further studies. 
 
Cell Cycle Assay. Our previous studies have indicated an apoptotic effect associated with 
withanolide-type steroids, and reported the first examples of WA-silyl ether analogues, 21 
and 22
18
 in HeLa cells. Moreover, WA has been reported to trigger the apoptotic cascade by 
extrinsic or intrinsic pathways, e.g., in promyelocytic leukemia HL-6022 and U937 cells,
23
 
prostate cancer cells,
24
 head and neck squamous carcinoma cells (HNSCC)
25
 and Caki cells.
26
 
In the present study, the cell cycle event mediated by two potent analogues, 21 and 22, was 
investigated on human ovarian cancer cell line A2780. It should be noted that 22 showed a 
very good selectivity on non-cancerous cells (SI 97.68) (Table 1, and Supporting 
Information, S47). Cell cycle analysis was carried out using NucleoCounter® NC-3000™ 
system by rapid quantification of DNA content which was measured using fluorescent 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI) stained cells. This assay will determine 
cell sorting at different phases of cell cycle. Results showed that both analogues, 21 and 22, 
induce a dose-dependent increase in DNA fragmentation as evidenced by the increase in the 
number of cells with low intensity DAPI signal in sub-G0/G1 as compared to control cells 
(Figure 1, and Supporting Information, S49). This is suggestive of cell death by apoptosis 
without indication of a cell cycle arrest in G0/G1 over 48 h contact time with the compounds.  
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Figure 1. Percentage of cells in sub-G1, G0/G1, S and G2 phases after performing two-step 
cell cycle assay on human ovarian cancer cells (A2780 cell line) with compounds 21 (A) and 
22 (B) at different concentrations. Data are based on 48 h exposure to compounds or vehicle 
control. Each column represents mean ± s. e. mean of n = 2. 
 
3. Structure-Activity Relationship Analysis. The previous reported SAR studies agree 
that an α,-unsaturated ketone on ring A, a 5,6-epoxide in ring B and an α,-unsaturated δ-
lactone on side-chain in the WA-framework
20
 are antitumor structural feature requirements, 
and more recently, acylation is reported to enhance cytotoxicity.
19
  
In this work, chemical modulation by incorporation of silicon on the WA-framework was 
investigated. Thus, taking into consideration the IC50 values against both cancer cell lines 
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assayed, the effect of silyl ether substituents was analyzed for each synthesized analogue (2-
34), according to the nature of the group attachment to silicon. The trends of the SAR study 
from this series of WA-silyl analogues on the A2789 cell line were as follows. Compounds 
carrying heterogeneous alkyl substituents on the silyl ether (7-10) displayed higher 
cytotoxicity than those with a homogeneous silyl ether (2-6). Indeed, replacement of 
dimethyloctyl or dimethylphenyl groups in the potent analogues 13 and 15 by a trihexyl, 
triisopropyl, or methyldiphenyl moiety led to the loss of activity (6, 12 and 29). Previous 
work revealed that oxidation of the secondary alcohol at C-4 of the WA framework plays an 
important role in cytotoxicity.
18
 Surprisingly, the 4-oxo-WA derivative 23 (7.3 nM) showed a 
4.4-fold increase in activity as compared to 1 (32.7 nM). Furthermore, to explore the effect of 
replacement the primary hydroxyl group at C-27 by a sylil ether, derivatives 24-34 were 
prepared from 23 (Scheme 4). These analogues showed a broad profile of inhibitory activities 
with IC50 values ranging from 35 nM to 25.17 µM, although all of them were significantly 
less potent than the congener 23 (IC50 7.3 nM) and lead compound 1 (IC50 32.7 nM). In 
general, silyl-analogues with a hydroxyl group at C-4 (3-9 and 18) are more potent than those 
with a ketone group (26-29, 31 and 32) at this position. 
Regarding the cisplatin-resistant cell line (A2780/CP70), SAR studies of this series of 
analogues revealed that compounds carrying a heterogeneous alkyl substituent on the silyl 
ether (7-10 and 13-15) displayed similar profiles (IC50 24.9-33.0 nM) to 1, indicating that 
activity was not greatly influenced by their corresponding silyl ether moiety on the 
withanolide skeleton. Analogues with a homogeneous alkyl substituent on the silyl ether (2-6, 
11 and 12) showed a great range of cytotoxic activity. In fact, replacement of the triethyl or 
tripropyl subtituent in potent compounds 2 and 3 by a trihexyl, di-tripropyl, or di-
methyldiphenyl moiety (compounds 6, 12, and 16) led to significant loss of activity. 
Moreover, analogue 23 was 30-fold more potent than the parent against the cisplatin-resistant 
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cell line, whereas silyl-analogues 24-34 (Scheme 4) were significantly less potent than their 
congener 23, as occurred on the A2780 cell line. Therefore, a heterogeneous alkyl substituent 
on the silyl ether is favorable versus a homogenous one for the A2789 cell line, with the 
DMOS and DMPS the best functional groups. On the other hand, the homogenous alkyl 
substituents, TES and TPRS are the best functional groups on the A2789/CP70 cell line. 
Compounds with a hydroxyl group at C-4 are favorites versus those oxidized at C-4 on both 
cell lines, except for compound 23. 
These results reveal that silylation of the WA-framework leads to a significant range of 
cytotoxic activity. Moreover, minor modifications on the silyl ether substituent, affecting 
spatial occupation at this site, had noteworthy repercussions on compound activity. 
Furthermore, silylation of the WA-framework leads to selectivity on both tumor cell lines. 
Moreover, taking into consideration that compounds with a silyl ether group increases 
hydrophobicity,
27
 WA-silyl analogues could present advantages as drug candidates.  
 
4. In silico ADME Predictions. Understanding pharmacokinetic properties (ADMET, 
absorption, distribution, metabolism, and excretion molecular properties) is an important step 
in drug discovery to select new lead/drug candidates, since potent in vitro activity along with 
enhanced ADMET profiles increase the probability of clinical success.28 Moreover, despite a 
great deal of research conducted on the potential anticancer properties of WA-related 
withanolides, there are only two reports of ADMET studies.
29,30 
The QikProp module of Schrödinger software
31
 was used for analyzing physicochemical 
and pharmacokinetic descriptors (ADME properties) of selected compounds (IC50 values ≤ 1 
µM on A2780 and A2780/CP70 cell lines) with the aim of increasing the success rate of 
compounds reaching further stages of development. A detailed account of these parameters is 
given in Table S50 of the Supporting Information. These parameters provide insights into key 
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aspects such as drug likeness, solubility, permeability, bioavailability predictions, oral 
absorption, metabolism, etc. One of the primary descriptors that were taken into account was 
#stars. The #stars descriptor informs about the number of properties of each compound that 
fail to remain within the recommended ranges, therefore, a lower number of #stars denotes a 
better drug-like molecule.
31
  
Thus, taking into consideration the IC50 values of the assayed series of analogues with 
higher cytotoxic effect than WA (IC50 < 34.7 nM on A2780 cell line), and #stars values (0 or 
1), compounds 2, 8, 17, 20, 22, 23 and 25 were selected to analyze their predicted 
pharmacokinetic properties (Table 2). Analogue 23 and the silyl ether analogue 25 as well as 
WA lie within the recommended range of known drugs for all the analyzed parameters (# 
stars = 0), whereas sylil ether analogue 2, 8, 17, 20 and 22 fail in the QPlogS displaying low 
aqueous solubility, although values for these analogues were near the upper limit of the 
recommended range. Nevertheless, these silyl analogues showed predicted intestinal 
absorption rate (QPPCaco) and apparent cell permeability (QPPMDK) greater than the lead 
compound WA, thus predicting good oral bioavailability. The lipophilicity is also an 
important physicochemical property requirement for a potential drug. It is expressed as 
QPlogPo/w and play a crucial role in absorption, bioavailability, hydrophobic drug-receptor 
interactions, metabolism, and toxicity.
32 
All the selected compounds log Po/w values lay 
within the permissible range. The predicted values for properties such as octanol/water 
partition (QPlogPo/w), gut-blood barrier permeability (QPPCaco, QPlogBB and 
QPPMDCK), human serum albumin binding (QPlogKhsa) and percent of human oral 
absorption (> 83%) were within ideal ranges. Therefore, compounds under study were 
predicted to have good drug-likeness, since they have mostly favorable pharmacokinetic 
properties, especially regarding membrane permeability and oral absorptivity.  
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Table 2. In silico ADME profile predictions of selected WA-analogues
a
 and their range/ 
recommended values.
b 
 
Property/ 
Descriptor 
1 2 8 17 20 22 23 25 
Range/ 
recommended 
values 
#stars 0 1 1 1 1 1 0 0 0-5 
QPlogBB -1.311 -1.072 -1.113 -1.253 -1.258 -087 -1.267 -1.156 -3.0 to 1.2 
QPPCaco 258.201 1060.23 759.53 550.181 600.427 996.046 243.685 711.663 <25 poor, 
>500 great 
QPPMDCK 114.484 526.993 367.48 259.339 285.031 492.595 107.544 342.512 <25 poor, 
>500 great 
QPlogKhsa 0.329 1.189 1.017 1.136 1.1 0.892 -0.13 0.827 -1.5 to 1.5 
QPlogPo/w 3.046 5.959 5.291 5.752 5.573 5.464 2.519 5.391 -2.0 to 6.5 
QPlogKp -3.842 -2.271 -2.635 -3.075 -2.816 -2.615 -3.977 -2.74 -8.0 to -1.0 
QPlogS -4.999 -7.586 -7.336 -7.379 -7.844 -6.713 -3.974 -6.489 -6.5 to 0.5 
#metab 4 4 4 4 5 3 3 3 1 to 8 
%HOA 87.948 90.068 83.565 83.76 83.39 86.682 84.413 83.643 >80% high 
<25% poor 
PSA 96.36 85.36 85.36 85.36 103.18 82.2 93.2 82.2 7.0 to 200.0 
SASA 718.234 906.765 874.31 88.418 949.884 877.558 711.717 882.911 300.0 to 
1,000.0 
Mol MW 470.605 584.867 554.8 570.84 638.918 582.851 468.589 582.851 130.0 to 
725.0 
#rotor 5 9 7 7 7 6 4 8 0 to 15 
donorHB 1 1 1 0 1 0 0 0 0.0 to 6.0 
accptHB 9.4 9.55 9.55 8.55 11.55 9.85 9.7 9.85 2.0 to 20.0 
volume 1396.689 1803.47 1709.1 1757.66 1903.72 1778.773 1383.64 1785.65 500.0 to 
2,000.0 
a
 WA-analogues exhibiting IC50 values lower than those for WA on A2780 and/or A2780 cell 
lines (IC50 < 32.7 nM), and #stars values between 0-1. 
b
 #star (number of property values that 
fall outside the 95% range of similar values for known drugs), QPlogBB (predicted 
brain/blood partition coefficient), QPPCaco2 (predicted human epithelial colorectal 
adenocarcinoma cell line permeability in nm/s), QPPMDCK (predicted Madin-Darby canine 
kidney permeability in nm/s), QPlogKhsa (predicted binding to human serum albumin), 
QPlogPo/w (predicted octanol/water partition coefficient), QPlogKp (skin permeability), 
QPlogS (predicted aqueous solubility), #metab (number of likely metabolic reactions), % 
HOA (predicted human oral absorption on 0 to 100%), PSA (Van der Waals surface area of 
polar nitrogen and oxygen atoms and carbonyl atoms), SASA (total solvent accessible surface 
area), MW (molecular weight), #rotor (number of non-trivial, non-hindered rotable bonds). 
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CONCLUSIONS 
The current study reports on our efforts to find new drug candidates for OC resistant to 
current treatments. Therefore, the synthesis and evaluation of a WA-silyl ether library, 
together with structure-activity relationship and in silico ADME studies, were employed to 
find drug candidates for the treatment of ovarian cancer. We have successfully identified a 
new generation of potent and selective WA-analogues with a significantly improved 
cytotoxic profile. In fact, ten WA-analogues exhibited higher potency than the lead 
compound and reference drug on the cisplatin-sensitive cell line, and more notable, fifteen 
analogues enhanced cytotoxic profile on the cisplatin-resistant cell line. Cell cycle analysis of 
two potent analogues revealed cell death by apoptosis without cell cycle arrest in G0/G1. 
Furthermore, the predicted pharmacokinetic properties highlight three analogues with great 
potential to become drug candidates: the 4-oxo-WA (23) exhibiting single-digit nanomolar 
potency on both cancer cell lines, and two potent silyl-ether analogues, 22 and 25, on A2780 
and A2780/CP70 cells, respectively. This potency is accompanied by an excellent selectivity 
index and favorable drug-likeness. Thus, analogues reported herein are promising candidates 
in anticancer drug development for OC that deserve further investigation. 
In summary, the current study provides an insight into the anticancer potential of WA-
analogues on OC, whether alone or in combination with clinical drugs, and support the 
increasingly important role that silicon will play in drug design. 
 
EXPERIMENTAL SECTION 
General Methods for Chemistry. Optical rotations were measured on a Perkin Elmer 241 
automatic polarimeter, in CHCl3 at 25 ºC, the []D values are given in units of 10
-1
 deg cm
2
 g
-
1
. 
1
H (500 MHz) and 
13
C (125 MHz) NMR spectra were recorded on a Bruker Avance 400 
spectrometer; chemical shifts are given in ppm and coupling constants in Hz. Solutions were 
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typically prepared in CDCl3 with chemical shifts referenced to deuterated solvent as an 
internal standard. EIMS and HREIMS were measured on a Micromass Autospec 
spectrometer, and ESIMS and HRESIMS (positive mode) were measured on a LCT Premier 
XE Micromass Autospec spectrometer. Silica gel 60 for column chromatography (particle 
size 15-40 and 63-200 µm), Polygram Sil G/UV254 used for analytical and preparative TLC, 
and HPTLC-Platten Nano-Sil 20 UV254 were purchased from Macherey-Nagel. Reactions 
were monitored by TLC, the spots were visualized by UV light and heating silica gel plates 
sprayed with H2O-H2SO4-AcH (1:4:20). Varian high-performance liquid chromatography 
(HPLC) equipment consisted of a ProStar 210 solvent delivery module, ProStar 335 
photodiode array detector, using an analytical Pursuit C18 column (2.0 x 100 mm, 3 µm) 
with a flow rate of 0.3 mL/min, and mixtures of acetonitrile-H2O as eluent. The degree of 
purity of the compounds was over 95% as indicated by the appearance of a single peak using 
HPLC. Unless otherwise noted, solvents and reagents were obtained from commercial 
suppliers and used without further purification. Anhydrous THF and Cl2CH2 were distilled 
from sodium/ benzophenone and calcium hydride ketyl under nitrogen, respectively. All 
solvents used were analytical grade from Panreac, and the reagents were purchased from 
Sigma Aldrich. Withaferin A (WA, 1), used as starting material, was isolated from the leaves 
of W. aristata as previously described.
16
 
 
Materials for Biological Studies. MTT and media for growing cell lines and all 
supplements were purchased from Sigma Aldrich, UK, and cell lines were purchased from 
ATCC. Non-cancerous cells were kindly donated by Prof Roger Phillips and Dr Simon 
Allison at the University of Huddersfield. Phosphate buffered saline (PBS), 50 µg/mL 
Annexin V-CF488A conjugate, Annexin V binding buffer (10 x concentrate), Solution 15 
(500 µg/mL Hoechst 33342), Solution 16 (500 µg/mL Propidium Iodide), Solution 10 (Lysis 
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buffer), Solution 11 (stabilization buffer), Solution 12 (500 µg/mL DAPI), NC-Slide A8™, 
NC-Slide A2™ glass slides and via-1 cassettes were bought from ChemoMetec, Denmark. 
NC-3000™ image cytometer was used to perform the assays.  
 
Cell Culture and Viability Assay. Cells were grown and maintained in DMEM or RPMI 
1640 medium supplemented with 10% fetal bovine serum, 5% penicillin streptomycin at 37 
ºC, 5% CO2/95% air as instructed by the suppliers. The cells were plated in 96-well culture 
plates at a density of 1 x 104 cells mL
-1
 and allowed to adhere at 37 ºC for 24 h. The 
following day, different doses of S186 or vehicle were added to the cells in varying 
concentrations of compounds and were further incubated for 96 hours. Following the 
aforementioned incubation time the supernatant was removed and MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added for 4 h. The ability of 
cells to form formazan crystals by active mitochondrial respiration was determined using a 
Microplate reader after dissolving the crystals in DMSO. Cytotoxicity was expressed as a 
relative percentage of the absorbance measured at 540 nm in the control and extract-treated 
cells. Data were presented as the mean ± s.e. mean. 
 
Two-step Cell Cycle Assay. Cells were seeded into T25 flasks containing 5 mL of 
complete media and were incubated for 24 h at 37 ºC. After 24 h elapsed cells were treated 
with vehicle control or compounds at different concentrations and left in the incubator for a 
further 48 h. Cells were then subjected to two-step cell cycle assay according to the 
manufacture’s instructions. Briefly, 1 mL of cells (1 x 106 cells/mL) was transferred to 
eppendorf tubes. In a separate eppendorf a mixture of 1960 µL of Lysis buffer (Solution 10) 
plus 40 µL of 500 µg/mL DAPI (Solution 12) was prepared. Eppendorfs containing cells 
were centrifuged at 400 g for 5 minutes, supernatant was removed and cells were re-
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suspended in 250 µL of the above mixture, mixed well and incubated at 37 ºC for 5 minutes. 
250 µL of stabilization buffer (Solution 11) was then added to the cells and mixed well. 10 
µL of each sample was then loaded on A8 slide and subjected to the two-step cell cycle assay 
using NC-3000™. 
 
Statistical Analysis. All results were expressed as means ± s.e. mean. Significant 
differences between groups were determined using unpaired Student’s t-test. Significance 
was set at p < 0.05. 
 
ADME Properties Predictions of WA-analogues. Prediction of descriptors related to 
adsorption, distribution, metabolism and excretion (ADME) properties of the compounds 
were predicted using the QikProp program (QikProp, version 5.3)
31
 in Fast mode and based 
on the method of Jorgensen
33,34
. Preparation of compounds and the 2D-to-3D conversion was 
performed using LigPrep tool, a module of the Small-Molecule Drug Discovery Suite in 
Schrödinger software package, followed by a MacroModel 12.01 Monte Carlo 
conformational search to locate the lowest energy conformation of each ligand. The program 
computes pharmacokinetic relevant properties such as octanol/water partitioning coefficient, 
aqueous solubility, brain/blood partition coefficient, Caco-2 cell permeability, serum protein 
binding, number of likely metabolic reactions, and others. Drug likeness (#stars), number of 
property descriptors from the full list of descriptors computed by the QikProp that fall outside 
the range of values determined for 95% of known drugs, was used as additional compound 
selection filter.  
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